SuperworthAtara Biotherapeutics EPS ATRA
Diluted earnings per share by quarter and over the last twelve months, from 2013.
- Last 12 months, to Jun 30, 2026
- −$1.18
- Latest quarter, Q2 FY26
- −$0.32
- −268% on a year earlier
- Fiscal year 2025
- $3.12
Atara Biotherapeutics' earnings per share was −$1.18 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.32, down 268% on the same quarter a year before.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $3.12 | n/a |
| FY2024 | −$12.87 | n/a |
| FY2023 | −$65.30 | n/a |
| FY2022 | −$55.75 | n/a |
| FY2021 | −$90.75 | n/a |
| FY2020 | −$105.25 | n/a |
| FY2019 | −$142.75 | n/a |
| FY2018 | −$131.00 | n/a |
| FY2017 | −$99.75 | n/a |
| FY2016 | −$68.75 | n/a |
| FY2015 | −$55.50 | n/a |
| FY2013 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.32 | −268% | −$1.18 | |
| Q1 FY26 | −$0.29 | −108% | −$0.67 | |
| Q4 FY25 | −$0.25 | n/a | $3.12 | |
| Q3 FY25 | −$0.32 | n/a | $2.18 | |
| Q2 FY25 | $0.19 | n/a | −$0.43 | |
| Q1 FY25 | $3.50 | n/a | −$3.72 | |
| Q4 FY24 | −$1.19 | n/a | −$12.87 | |
| Q3 FY24 | −$2.93 | n/a | −$25.67 | |
| Q2 FY24 | −$3.10 | n/a | −$39.14 | |
| Q1 FY24 | −$5.65 | n/a | −$52.95 | |
| Q4 FY23 | −$13.99 | n/a | −$65.30 | |
| Q3 FY23 | −$16.40 | n/a | −$69.31 |
Against its peers
Companies in Healthcare nearest Atara Biotherapeutics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| ATRAAtara Biotherapeutics | −$1.18 | |
| ICCCImmucell | $0.08 | −58% a year |
| KEQUKewaunee Scientific | $2.76 | −33% a year |
| LFVNLifevantage | $0.40 | −46% a year |
| SPROSpero Therapeutics | $0.11 | |
| APTAlpha Pro Tech | $0.41 | +24% a year |
| ATNMActinium Pharmaceuticals | $0.36 | |
| NEPHNephros | $0.16 | +33% a year |
| PDEXPro DEX | $4.11 | +52% a year |
| PLXProtalix BioTherapeutics | $0.23 | +283% a year |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| Peer median | $0.38 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Atara Biotherapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.